What can help cartilage soreness, with or without surgery

What can help before an operation?

Shorter walks, planned breaks, gentle bending, and slow strength work can help you stay active. Physical therapy may help when weak muscles or poor motion add to the ache. Losing some weight can ease the load when that applies to you.

Chondromalacia treatment means care for softened or damaged cartilage under the kneecap. It may start with easier activity and strength work. If the knee catches, swells often, or loses motion, you'll need an exam before doing more.

Home care has limits, and that's all right.

Which non-surgical choices does QC Kinetix provide?

QC Kinetix offers regenerative treatments, its name for non-surgical care that may be prepared from your own blood. Platelet-rich plasma is one such choice. To prepare it, the clinic spins a small blood sample, keeps the part with more platelets, and places that part in the sore joint during your appointment at the clinic. The concentrated form has a higher platelet level.

These choices are also called biologic therapies or natural pain treatments, which here means the blood-based care just described. A medical provider is the clinician who'll examine you before deciding whether either form fits. The aim is easier movement with less soreness. Ask what follow-up may cost and how long chores might be limited.

Don't agree until the time, price, and likely benefit are clear.

What is microfracture surgery?

During microfracture surgery, the surgeon makes small holes in the bone under a damaged cartilage spot. Repair tissue may fill that spot, though the new tissue differs from the original smooth covering. Recovery can take many months. You may have to avoid standing on that leg, so walking may be limited and crutches may be needed.

This operation is usually discussed for one clear damaged spot instead of wear throughout the joint. Results can change with time, and another operation may still be needed. Before deciding, ask when you could walk, drive, work, and start therapy again.

Surgery takes time as well as money.

What if the report says osteochondral defect?

An osteochondral defect means cartilage and the bone right below it are damaged. A surgeon may discuss moving cartilage and bone from another area or using donor tissue. The size, depth, and location help the surgeon choose what to discuss.

Those operations aren't the same as care aimed mainly at soreness. They're also different from joint replacement, which may be used when wear has spread through much of the joint. If surgery comes up, ask what tissue is moved, how long it needs protection, and what care follows if it doesn't work.

The recovery has to fit your life.

Sources

1. A JBJS evidence-based review of chondral lesions of the knee sets management by lesion size, location, limb alignment and rotation, and patient demand rather than by product: osteochondral autograft transfer is described as durable and predictable for smaller lesions (under 2 cm2) in young active patients, while lesions of 2 cm2 or more are typically treated with osteochondral allograft transplantation, particulated juvenile articular cartilage, or matrix-associated chondrocyte implantation, with favourable mid- and long-term results reported for allograft or MACI in large lesions of 3 cm2 or more.

   Dekker TJ, et al. — Chondral Lesions of the Knee: An Evidence-Based Approach.. J Bone Joint Surg Am, 2021. DOI: 10.2106/JBJS.20.01161.

2. The Cochrane review of surgical interventions for isolated cartilage defects of the knee in adults found only three randomised trials, all comparing mosaicplasty with microfracture, reporting 133 participants in total with a mean defect area of 2.8 cm2. It found NO randomised trials of allograft transplantation or drilling at all, judged every trial at high or unclear risk of bias, and rated the quality of evidence very low for every outcome.

   Gracitelli GC, et al. — Surgical interventions (microfracture, drilling, mosaicplasty, and allograft transplantation) for treating isolated cartilage defects of the knee in adults.. Cochrane Database Syst Rev, 2016. DOI: 10.1002/14651858.CD010675.pub2.

3. FDA biologics licence BL 125603 (Vericel) describes MACI verbatim as "an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults." The licensed indication is a two-stage surgical implantation for full-thickness DEFECTS of the knee in adults. It is not an injection, it is not licensed for osteoarthritis, and it is not licensed for any joint other than the knee.

   U.S. Food and Drug Administration — MACI (autologous cultured chondrocytes on porcine collagen membrane). FDA, Center for Biologics Evaluation and Research, 2024.

4. FDA's consumer alert states verbatim of stem cell products, exosome products, adipose-derived stromal vascular fraction, umbilical cord blood, Wharton's Jelly and amniotic fluid products: "None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain." The only stem cell products carrying FDA licensure are blood-forming cells derived from umbilical cord blood, licensed only for disorders of blood production, and there are currently no licensed exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, Consumers (Biologics), 2020.

5. At 14 to 15 years, the Norwegian multicentre randomised trial of 80 patients with a single symptomatic femoral condyle cartilage defect found no significant difference between autologous chondrocyte implantation and microfracture on any clinical scoring system. There were 17 failures in the ACI group versus 13 after microfracture, and more total knee replacements had been needed after ACI (6 versus 3).

   Knutsen G, et al. — A Randomized Multicenter Trial Comparing Autologous Chondrocyte Implantation with Microfracture: Long-Term Follow-up at 14 to 15 Years.. J Bone Joint Surg Am, 2016. DOI: 10.2106/JBJS.15.01208.

6. A prospective cohort of 110 patients treated with microfracture for a focal chondral defect was evaluated at a median of 12 years. Scores improved significantly from baseline and did not differ from the 5-year results, but 43 patients had needed further knee surgery including seven knee replacements, 50 had a poor long-term outcome, and normal knee function was generally not achieved. The authors called for caution in recommending microfracture.

   Solheim E, et al. — Results at 10-14 years after microfracture treatment of articular cartilage defects in the knee.. Knee Surg Sports Traumatol Arthrosc, 2016. DOI: 10.1007/s00167-014-3443-1.

7. A systematic review of 27 studies of arthroscopic joint-preservation techniques for chondral lesions of the HIP found survival (no revision and no conversion to hip replacement) ranging from 59.1% to 100% for microfracture, 92.9% to 100% for autologous matrix-induced chondrogenesis and 94.4% to 95.7% for microfracture with a chitosan scaffold, on mostly non-comparative evidence.

   Akhtar M, et al. — Outcomes of Arthroscopic Joint Preservation Techniques for Chondral Lesions in the Hip: An Updated Systematic Review.. Arthroscopy, 2024. DOI: 10.1016/j.arthro.2023.11.019.